Breaking News, Trials & Filings

Novavax NanoFlu Vax Achieves all Phase III Primary Endpoints

Demonstrates non-inferior immunogenicity to Fluzone Quadrivalent against all four influenza virus strains included in the vaccine.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced complete results from a pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M adjuvant.   The trial evaluated the immunogenicity and safety of NanoFlu in older adults compared to a leading U.S.-licensed quadrivalent influenza vaccine. In the complete analysis, NanoFlu was well-tolerated and produced significan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters